LERIBANE Drug Patent Profile
✉ Email this page to a colleague
When do Leribane patents expire, and what generic alternatives are available?
Leribane is a drug marketed by Novast Labs and is included in one NDA.
The generic ingredient in LERIBANE is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LERIBANE?
- What are the global sales for LERIBANE?
- What is Average Wholesale Price for LERIBANE?
Summary for LERIBANE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
DailyMed Link: | LERIBANE at DailyMed |
Pharmacology for LERIBANE
Drug Class | Estrogen Progestin |
Mechanism of Action | Estrogen Receptor Agonists |
US Patents and Regulatory Information for LERIBANE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novast Labs | LERIBANE | ethinyl estradiol; norethindrone acetate | TABLET;ORAL | 203435-002 | Jun 3, 2016 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Novast Labs | LERIBANE | ethinyl estradiol; norethindrone acetate | TABLET;ORAL | 203435-001 | Jun 3, 2016 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |